Roller R J, Kern F
Gastroenterology. 1977 Apr;72(4 Pt 1):661-5.
This study was undertaken because of reports of a marked increase in fecal bile acid excretion by children with cystic fibrosis. We attempted to confirm this finding by performing [1-14C]cholylglycine breath tests and by measuring fecal bile acid and fat excretion in patients with cystic fibrosis and acquired pancreatic insufficiency. Studies were done when patients were taking pancreatic enzymes (Cotazym) and also without medication. 14CO2 excretion in breath was normal in patients with acquired pancreatic insufficiency and even lower in cystic fibrosis, both with and without Cotazym therapy. Fecal bile acid excretion was slightly elevated in both groups without Cotazym and became normal with Cotazym in patients with acquired pancreatic insufficiency. Steatorrhea was present in both patient groups and improved during Cotazym therapy. Bile acid malabsorption in cystic fibrosis and acquired pancreatic insufficiency is minimal and probably not clinically important.
本研究是由于有报告称囊性纤维化患儿粪便胆汁酸排泄显著增加而开展的。我们试图通过进行[1-14C]甘氨胆酸呼气试验以及测量囊性纤维化和获得性胰腺功能不全患者的粪便胆汁酸和脂肪排泄来证实这一发现。研究在患者服用胰酶(Cotazym)时以及未用药时进行。获得性胰腺功能不全患者呼气中14CO2排泄正常,囊性纤维化患者无论是否接受Cotazym治疗,其呼气中14CO2排泄甚至更低。两组未服用Cotazym时粪便胆汁酸排泄略有升高,获得性胰腺功能不全患者服用Cotazym后粪便胆汁酸排泄恢复正常。两组患者均存在脂肪泻,服用Cotazym治疗期间有所改善。囊性纤维化和获得性胰腺功能不全患者的胆汁酸吸收不良程度轻微,可能在临床上并不重要。